BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in March.
37th Annual ROTH Conference
Monday, March 17, 2025
The Laguna Cliffs Marriott, Dana Point, CA
Management will present at 4:00 PM PDT
KeyBanc Healthcare Forum
Wednesday, March 19, 2025
Virtual Event
Management will present at 1:30 PM EDT
Oppenheimer 35th Annual Healthcare MedTech & Services Conference
Thursday, March 20, 2025
Virtual Event
Management will present at 10:00 AM EDT
About LeMaitre
LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com.
LeMaitre is a registered trademark of LeMaitre Vascular, Inc.
| Last Trade: | US$94.48 |
| Daily Change: | -0.54 -0.57 |
| Daily Volume: | 91,004 |
| Market Cap: | US$2.140B |
August 05, 2025 May 05, 2025 May 01, 2025 April 01, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
